Inborn errors of metabolism and expanded newborn screening: review and update

References

• Dronamraju K. Profiles in genetics: Archibald E. Garrod (1857–1936). Am J Hum Genet 1992;51:216–9
   Google Scholar
• Sharer JD, Korf BR. Biochemical genetics. Curr Protoc Hum Genet 2012; Chapter 17:Unit 17
   Google Scholar
• Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. Lancet 1902;2:1616–20
   Google Scholar
• Beadle GW, Tatum EL. Genetic control of biochemical reactions in Neurospora. Proc Natl Acad Sci USA 1941;27:499–506
   PubMedGoogle Scholar
• Tatum EL. A case history in biological research. Science 1959;129:1711–5
   PubMedGoogle Scholar
• Singer M, Berg P. George Beadle: from genes to proteins. Nat Rev Genet 2004;5:949–54
   Google Scholar
• Medes G. A new error of tyrosine metabolism: tyrosinosis. The intermediary metabolism of tyrosine and phenylalanine. Biochem J 1932;26:917–40
   PubMedGoogle Scholar
• van Creveld S. Investigations on glycogen disease. Arch Dis Child 1934;9:9–26
   Google Scholar
• Folling I. The discovery of phenylketonuria. Acta Paediatrica 1994;407:4–10
   Google Scholar
• Pampols T. Inherited metabolic rare disease. Adv Exp Med Biol 2010;686:397–431
   Google Scholar
• Saudubray JM, Nassogne MC, de Lonlay P, Touati G. Clinical approach to inherited metabolic disorders in neonates: an overview. Semin Neonatol 2002;7:3–15
   Google Scholar
• Kaleem Z, Hassan A. Multiple lytic bone lesions in an 85-year-old man: type 1 Gaucher disease, adult onset (nonneuronopathic form). Arch Pathol Lab Med 2005;129:e148–50
   Google Scholar
• Holmes JM, Houghton CR, Woolf AL. A myopathy presenting in adult life with features suggestive of glycogen storage disease. J Neurol Neurosurg Psychiatry 1960;23:302–11
   Google Scholar
• Trend PS, Wiles CM, Spencer GT, et al. Acid maltase deficiency in adults. Diagnosis and management in five cases. Brain 1985;108:845–60
   Google Scholar
• Salem B, Thaisetthawatkul P, Fernandes JA, McComb RD. Adult-onset acid maltase deficiency with isolated axial muscle involvement. J Clin Neuromuscul Dis 2010;12:30–5
   Google Scholar
• Lightman NI, Schooley RT. Adult-onset acid maltase deficiency. Case report of an adult with severe respiratory difficulty. Chest 1977;72:250–2
   Google Scholar
• Swash M, Schwartz MS, Apps MC. Adult onset acid maltase deficiency. Distribution and progression of clinical and pathological abnormality in a family. J Neurol Sci 1985;68:61–74
   Google Scholar
• Kurz D, Aguzzi A, Scherer TA. Decompensated cor pulmonaleas the first manifestation of adult-onset myopathy. Respiration 1998;65:317–9
   Google Scholar
• Miyamoto Y, Etoh Y, Joh R, et al. Adult-onset acid maltase deficiency in siblings. Acta Pathol Jpn 1985;35:1533–42
   Google Scholar
• Felice KJ, Alessi AG, Grunnet ML. Clinical variability in adult-onset acid maltase deficiency: report of affected sibs and review of the literature. Medicine (Baltimore) 1995;74:131–5
   Google Scholar
• Patil R, Depriest JL. Visual hallucinations in a patient with adult onset acid maltase deficiency disorder. J Gen Intern Med 2009;24:683–6
   Google Scholar
• Asola MR. A diver unconscious after gastroenteritis. Lancet 1995;346:1338
   Google Scholar
• Hall DA, Ringel SP. Adult nonketotic hyperglycinemia (NKH) crisis presenting as severe chorea and encephalopathy. Mov Disord 2004;19:485–6
   Google Scholar
• Vantyghem MC, Dobbelaere D, Mention K, et al. Endocrine manifestations related to inherited metabolic diseases in adults. Orphanet J Rare Dis 2012;7:(11)1--19
   Google Scholar
• Sedel F, Barnerias C, Dubourg O, et al. Peripheral neuropathy and inborn errors of metabolism in adults. J Inherit Metab Dis 2007;30:642–53
   Google Scholar
• Coker SB. The diagnosis of childhood neurodegenerative disorders presenting as dementia in adults. Neurology 1991;41:794–8
   Google Scholar
• Kelley BJ, Boeve BF, Josephs KA. Young-onset dementia: demographic and etiologic characteristics of 235 patients. Arch Neurol 2008;65:1502–8
   PubMedGoogle Scholar
• Sedel F, Baumann N, Turpin JC, et al. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis 2007;30:631–41
   PubMed Web of Science ®Google Scholar
• Sedel F, Lyon-Caen O, Saudubray JM. Therapy insight: inborn errors of metabolism in adult neurology–a clinical approach focused on treatable diseases. Nat Clin Pract Neurol 2007;3:279–90
   Google Scholar
• Sedel F, Fontaine B, Saudubray JM, Lyon-Caen O. Hereditary spastic paraparesis in adults associated with inborn errors of metabolism: a diagnostic approach. J Inherit Metab Dis 2007;30:855–64
   Google Scholar
• Gray RG, Preece MA, Green SH, et al. Inborn errors of metabolism as a cause of neurological disease in adults: an approach to investigation. J Neurol Neurosurg Psychiatry 2000;69:5–12
   Google Scholar
• Sedel F, Tourbah A, Fontaine B, et al. Leukoencephalopathies associated with inborn errors of metabolism in adults. J Inherit Metab Dis 2008;31:295–307
   Google Scholar
• Bachelot A, Chakthoura Z, Rouxel A, et al. Classical forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults. Horm Res 2008;69:203–11
   Google Scholar
• Auchus RJ. Congenital adrenal hyperplasia in adults. Curr Opin Endocrinol Diabetes Obes 2010;17:210–6
   Google Scholar
• Rapola J. Lysosomal storage diseases in adults. Pathol Res Pract 1994;190:759–66
   Google Scholar
• Eyskens F. Rare inborn errors of metabolism in adults: the lysosomal storage disorders. Acta Clin Belg 2009;64:534–9
   PubMed Web of Science ®Google Scholar
• Pears JS, Jung RT, Hopwood D, et al. Glycogen storage disease diagnosed in adults. Q J Med 1992;82:207–22
   Google Scholar
• Talente GM, Coleman RA, Alter C, et al. Glycogen storage disease in adults. Ann Intern Med 1994;120:218–26
   Google Scholar
• Finsterer J. Leigh and Leigh-like syndrome in children and adults. Pediatr Neurol 2008;39:223–35
   PubMed Web of Science ®Google Scholar
• Moog U, van Mierlo I, van Schrojenstein Lantman-de Valk HM, et al. Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems? Am J Med Genet C Semin Med Genet 2007;145C:293–301
   PubMed Web of Science ®Google Scholar
• Krasnewich D, O'Brien K, Sparks S. Clinical features in adults with congenital disorders of glycosylation type Ia (CDG-Ia). Am J Med Genet C Semin Med Genet 2007;145C:302–6
   PubMed Web of Science ®Google Scholar
• Pearl PL, Capp PK, Novotny EJ, Gibson KM. Inherited disorders of neurotransmitters in children and adults. Clin Biochem 2005;38:1051–8
   Google Scholar
• Pearl PL, Novotny EJ, Acosta MT, et al. Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol 2003;54:S73–80
   Google Scholar
• Ose L. Familial hypercholesterolemia from children to adults. Cardiovasc Drugs Ther 2002;16:289–93
   Google Scholar
• Kumar A, Riely CA. Inherited liver diseases in adults. West J Med 1995;163:382–6
   Google Scholar
• Morrison ED, Kowdley KV. Genetic liver disease in adults. Early recognition of the three most common causes. Postgrad Med 2000;107:147–52, 55, 58–9
   Web of Science ®Google Scholar
• Garg U, Dasouki M. Expanded newborn screening of inherited metabolic disorders by tandem mass spectrometry: clinical and laboratory aspects. Clin Biochem 2006;39:315–32
   PubMedGoogle Scholar
• Sanderson S, Green A, Preece MA, Burton H. The incidence of inherited metabolic disorders in the West Midlands, UK. Arch Dis Child 2006;91:896–9
   PubMed Web of Science ®Google Scholar
• Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics 2000;105:e10 (1--6)
   Google Scholar
• Dionisi-Vici C, Rizzo C, Burlina AB, et al. Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. J Pediatr 2002;140:321–7
   PubMed Web of Science ®Google Scholar
• Moammar H, Cheriyan G, Mathew R, Al-Sannaa N. Incidence and patterns of inborn errors of metabolism in the Eastern Province of Saudi Arabia, 1983–2008. Ann Saudi Med 2010;30:271–7
   PubMed Web of Science ®Google Scholar
• Lee HC, Mak CM, Lam CW, et al. Analysis of inborn errors of metabolism: disease spectrum for expanded newborn screening in Hong Kong. Chin Med J (Engl) 2011;124:983–9
   PubMed Web of Science ®Google Scholar
• Nagaraja D, Mamatha SN, De T, Christopher R. Screening for inborn errors of metabolism using automated electrospray tandem mass spectrometry: study in high-risk Indian population. Clin Biochem 2010;43:581–8
   PubMed Web of Science ®Google Scholar
• Tan IK, Chio LF, Loh FC, et al. Inborn errors of metabolism in Singapore. J Inherit Metab Dis 1995;18:341–6
   Google Scholar
• Tan IK, Gajra B, Lim MS. Study of inherited metabolic disorders in Singapore – 13 years experience. Ann Acad Med Singapore 2006;35:804–13
   PubMed Web of Science ®Google Scholar
• Wasant P, Naylor EW, Liammongkolkul S. Detection of inherited metabolic disorders via tandem mass spectrometry in Thai infants. Southeast Asian J Trop Med Public Health 1999;30:154–9
   Google Scholar
• Wasant P, Svasti J, Srisomsap C, et al. Inherited metabolic disorders in Thailand–Siriraj experience. Southeast Asian J Trop Med Public Health 1999;30:124–37
   Google Scholar
• Han LS, Ye J, Qiu WJ, et al. Selective screening for inborn errors of metabolism on clinical patients using tandem mass spectrometry in China: a four-year report. J Inherit Metab Dis 2007;30:507–14
   PubMed Web of Science ®Google Scholar
• Pang CP, Ng CF. Maple syrup urine disease in Hong Kong. Aust Paediatr J 1987;23:205
   Google Scholar
• Pang CP, Law LK, Mak YT, et al. Biochemical investigation of young hospitalized Chinese children: results over a 7-year period. Am J Med Genet 1997;72:417–21
   Google Scholar
• Tang NL, Hui J, Law LK, et al. Overview of common inherited metabolic diseases in a Southern Chinese population of Hong Kong. Clin Chim Acta 2001;313:195–201
   Google Scholar
• Gu X, Wang Z, Ye J, et al. Newborn screening in China: phenylketonuria, congenital hypothyroidism and expanded screening. Ann Acad Med Singapore 2008;37:107–4
   Google Scholar
• Niu DM, Chien YH, Chiang CC, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis 2010;33:S295–305
   PubMed Web of Science ®Google Scholar
• Yoon HR, Lee KR, Kim H, et al. Tandem mass spectrometric analysis for disorders in amino, organic and fatty acid metabolism: two year experience in South Korea. Southeast Asian J Trop Med Public Health 2003;34:115–20
   Google Scholar
• Yamaguchi S. Newborn screening in Japan: restructuring for the new era. Ann Acad Med Singapore 2008;37:13–15
   PubMedGoogle Scholar
• Rama Devi AR, Naushad SM. Newborn screening in India. Indian J Pediatr 2004;71:157–60
   Google Scholar
• Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003;348:2304–12
   PubMed Web of Science ®Google Scholar
• Schulze A, Lindner M, Kohlmuller D, et al. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 2003;111:1399–406
   PubMed Web of Science ®Google Scholar
• Zytkovicz TH, Fitzgerald EF, Marsden D, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 2001;47:1945–55
   PubMed Web of Science ®Google Scholar
• Bickel H, Gerrard J, Hickmans EM. The influence of phenylalanine intake on the chemistry and behaviour of a phenyl-ketonuric child. Acta Paediatr 1954;43:64–77
   Google Scholar
• Armstrong MD, Low NL, Bosma JF. Studies on phenylketonuria. Further observations on the effect of phenylalanine-restricted diet on patients with phenylketonuria. Am J Clin Nutr 1957;5:543–54
   PubMed Web of Science ®Google Scholar
• Armstrong MD, Shaw KN, Robinson KS. Studies on phenylketonuria. The excretion of o-hydroxyphenylacetic acid in phenylketonuria. J Biol Chem 1955;213:797–804
   PubMed Web of Science ®Google Scholar
• Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338–43
   PubMed Web of Science ®Google Scholar
• Rule JT. Screening of newborn infants for metabolic disease: committee on fetus and newborn. Pediatrics 1965;35:499–501
   Google Scholar
• Pediatrics AAo. Statement on compulsory testing of newborn infants for hereditary metabolic disorders. Pediatrics 1967;39:623–4
   Google Scholar
• MacCready R. Phenylketonuria screening program. N Engl J Med 1963;269:52–6
   Web of Science ®Google Scholar
• Comeau AM, Larson C, Eaton RB. Integration of new genetic diseases into statewide newborn screening: New England experience. Am J Med Genet C Semin Med Genet 2004;125C:35–41
   PubMed Web of Science ®Google Scholar
• Wilson JMG, Jungner G. The principles and practice of screening for disease. World Health Organization 1968 http://www.who.int/bulletin/volumes/86/4/07-050112bp.pdf
   Google Scholar
• World Health Organization. Screening for inborn errors of metabolism. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1968;401:1–57
   Google Scholar
• Brosco JP, Mattingly M, Sanders LM. Impact of specific medical interventions on reducing the prevalence of mental retardation. Arch Pediatr Adolesc Med 2006;160:302–9
   Google Scholar
• Leonard H, Wen X. The epidemiology of mental retardation: challenges and opportunities in the new millennium. Ment Retard Dev Disabil Res Rev 2002;8:117–34
   PubMedGoogle Scholar
• Dussault JH, Coulombe P, Laberge C, et al. Preliminary report on a mass screening program for neonatal hypothyroidism. J Pediatr 1975;86:670–4
   PubMed Web of Science ®Google Scholar
• Therrell BL, Adams J. Newborn screening in North America. J Inherit Metab Dis 2007;30:447–65
   PubMed Web of Science ®Google Scholar
• Vilarinho L, Rocha H, Sousa C, et al. Four years of expanded newborn screening in Portugal with tandem mass spectrometry. J Inherit Metab Dis 2010;33(Suppl 3):133--8
   Google Scholar
• Wilcken B, Smith A, Brown DA. Urine screening for aminoacidopathies: is it beneficial? Results of a long-term follow-up of cases detected bny screening one millon babies. J Pediatr 1980;97:492–7
   Google Scholar
• Wilcken B. Neonatal screeing in Australia. Southeast Asian J Trop Med Public Health 1999;30:41–2
   Google Scholar
• Wilcken B, Chalmers G. Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet 1985;2:1319–21
   Google Scholar
• Gregg RG, Wilfond BS, Farrell PM, et al. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet 1993;52:616–26
   Google Scholar
• Kosel S, Burggraf S, Fingerhut R, et al. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency. Clin Chem 2005;51:298–304
   Google Scholar
• Thomson JJ. Positive Electricity. Philos Mag 1909;18:821–45
   Google Scholar
• Yost RA, Enke GCJ. Selected ion fragmentation with a tandem quadrupole mass spectrometer. J Am Chem Soc 1978;100:2274--5
   Web of Science ®Google Scholar
• Yamashita M, Fenn JB. Negative ion productlon with the electrospray ion source. J Phys Chem 1984;88:4611–5
   Google Scholar
• Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 1990;13:321–4
   PubMed Web of Science ®Google Scholar
• Chace DH, Millington DS, Terada N, et al. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem 1993;39:66–71
   PubMed Web of Science ®Google Scholar
• Chace DH, Hillman SL, Millington DS, et al. Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectrometry. Clin Chem 1995;41:62–8
   Google Scholar
• Chace DH, Hillman SL, Van Hove JL, Naylor EW. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997;43:2106–13
   Web of Science ®Google Scholar
• Pollitt RJ, Green A, McCabe CJ, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997;1:i–iv, 1-202
   PubMedGoogle Scholar
• Rashed MS, Rahbeeni Z, Ozand PT. Application of electrospray tandem mass spectrometry to neonatal screening. Semin Perinatol 1999;23:183–93
   PubMed Web of Science ®Google Scholar
• Pandor A, Eastham J, Beverley C, et al. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 2004;8:1–121
   Google Scholar
• Hanley WB, Demshar H, Preston MA, et al. Newborn phenylketonuria (PKU) Guthrie (BIA) screening and early hospital discharge. Early Hum Dev 1997;47:87–96
   Google Scholar
• Feuchtbaum L, Cunningham G. Economic evaluation of tandem mass spectrometry screening in California. Pediatrics 2006;117:S280–6
   PubMed Web of Science ®Google Scholar
• Wiley V, Carpenter K, Wilcken B. Newborn screening with tandem mass spectrometry: 12 months' experience in NSW Australia. Acta Paediatr 1999;88:48–51
   Google Scholar
• Marsden D. Expanded newborn screening by tandem mass spectrometry: the Massachusetts and New England experience. Southeast Asian J Trop Med Public Health 2003;34:111–4
   Google Scholar
• Bodamer OA, Hoffmann GF, Lindner M. Expanded newborn screening in Europe 2007. J Inherit Metab Dis 2007;30:439–44
   PubMed Web of Science ®Google Scholar
• la Marca G, Malvagia S, Casetta B, et al. Progress in expanded newborn screening for metabolic conditions by LC-MS/MS in Tuscany: update on methods to reduce false tests. J Inherit Metab Dis 2008;31:S395–404
   Google Scholar
• Slaughter JL, Espinoza L, Molinero I, et al. Utilization of blood spot testing for metabolic-genetic disorders in Honduras: is it time for newborn screening? J Child Neurol 2010;25:306–11
   Google Scholar
• Eggertson L. Canada lags on newborn screening. CMAJ 2005;173:23
   Google Scholar
• Hanley WB. Newborn screening in Canada – Are we out of step? Paediatr Child Health 2005;10:203–7
   Google Scholar
• American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system. Genet Med 2006;8:1S–252
   Google Scholar
• Padilla CD, Therrell BL. Newborn screening in the Asia Pacific region. J Inherit Metab Dis 2007;30:490–506
   PubMed Web of Science ®Google Scholar
• Aoki K. Newborn screening in Japan. Southeast Asian J Trop Med Public Health 2003;34(Suppl 3):80
   Google Scholar
• Shigematsu Y, Hirano S, Hata I, et al. Newborn mass screening and selective screening using electrospray tandem mass spectrometry in Japan. J Chromatogr B Analyt Technol Biomed Life Sci 2002;776:39–48
   PubMed Web of Science ®Google Scholar
• Chen RG, Sun M, Ni YY. Neonatal hypothyroidism, phenylketonuria and galactosemia screening in metropolitan Shanghai. Chin Med J 1984;97:61–5
   Google Scholar
• Chen RG. The initiation and progress of phenylketonuria programmes in China. Hong Kong Med J 1996;2:282–4
   Google Scholar
• Zheng S, Song M, Wu L, et al. China: public health genomics. Public Health Genomics 2010;13:269–75
   Google Scholar
• Cao Y, Yuan P, Wang YP, et al. The profile of newborn screening coverage in China. J Med Screen 2009;16:163–6
   Google Scholar
• Gu XF, Chen RG. Current status of neonatal screening in China. J Med Screen 1999;6:186–7
   Google Scholar
• Gu XF, Ye J, Han LS, Qiu WJ. Neonatal screening for inborn errors of metabolism in Shanghai. J Chin Pediatr 2009;27:101–5
   Google Scholar
• Hwu WL, Huang AC, Chen JS, et al. Neonatal screening and monitoring system in Taiwan. Southeast Asian J Trop Med Public Health 2003;34:91–3
   Google Scholar
• Kemper AR, Hwu WL, Lloyd-Puryear M, Kishnani PS. Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatrics 2007;120:e1327–34
   PubMed Web of Science ®Google Scholar
• Chien YH, Chiang SC, Zhang XK, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008;122:e39–45
   PubMed Web of Science ®Google Scholar
• Lin HY, Chong KW, Hsu JH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2009;2:450–6
   PubMed Web of Science ®Google Scholar
• Hwu WL, Chien YH, Lee NC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936 + 919G > A (IVS4 + 919G > A). Hum Mutat 2009;30:1397–405
   PubMed Web of Science ®Google Scholar
• Hwu WL, Chien YH, Lee NC. Newborn screening for neuropathic lysosomal storage disorders. J Inherit Metab Dis 2010;33:381–6
   PubMed Web of Science ®Google Scholar
• Chien YH, Lee NC, Huang HJ, et al. Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr 2011;158:1023–7 e1
   PubMed Web of Science ®Google Scholar
• Chiang SC, Hwu WL, Lee NC, et al. Algorithm for Pompe disease newborn screening: results from the Taiwan screening program. Mol Genet Metab 2012;106:281–6
   PubMed Web of Science ®Google Scholar
• Chiang SH, Fan ML, Hsiao KJ. External quality assurance programme for newborn screening of glucose-6-phosphate dehydrogenase deficiency. Ann Acad Med Singapore 2008;37:84–4
   Google Scholar
• Lam ST, Cheng ML. Neonatal screening in Hong Kong and Macau. Southeast Asian J Trop Med Public Health 2003;34:73–5
   PubMedGoogle Scholar
• Walter JH, Patterson A, Till J, et al. Bloodspot acylcarnitine and amino acid analysis in cord blood samples: efficacy and reference data from a large cohort study. J Inherit Metab Dis 2009;32:95–101
   PubMed Web of Science ®Google Scholar
• Mak CM, Lam CW, Law CY, et al. Parental attitudes on expanded newborn screening in Hong Kong. Public Health 2012;126:954–9
   Google Scholar
• Mak CM, Lam C, Siu W, et al. OPathPaed service model for expanded newborn screening in Hong Kong SAR, China. Br J Biomed Sci 2013;70:84–8
   Web of Science ®Google Scholar
• Solanki KK. Training programmes for developing countries. J Inherit Metab Dis 2007;30:596–9
   Google Scholar
• Padilla CD, Therrell BL Jr. Consolidating newborn screening efforts in the Asia Pacific region: Networking and shared education. J Community Genet 2012;3:35–45
   Google Scholar
• Rao NA, Devi AR, Savithri HS, et al. Neonatal screening for amino acidaemias in Karnataka, south India. Clin Genet 1988;34:60–3
   Google Scholar
• Pitt JJ. Newborn screening. Clin Biochem Rev 2010;31:57–68
   PubMedGoogle Scholar
• Strnadova KA, Holub M, Muhl A, et al. Long-term stability of amino acids and acylcarnitines in dried blood spots. Clin Chem 2007;53:717–22
   Google Scholar
• Fingerhut R, Ensenauer R, Roschinger W, et al. Stability of acylcarnitines and free carnitine in dried blood samples: implications for retrospective diagnosis of inborn errors of metabolism and neonatal screening for carnitine transporter deficiency. Anal Chem 2009;81:3571–5
   PubMed Web of Science ®Google Scholar
• De Jesus VR, Chace DH, Lim TH, et al. Comparison of amino acids and acylcarnitines assay methods used in newborn screening assays by tandem mass spectrometry. Clin Chim Acta 2010;411:684–9
   Google Scholar
• Centers for Disease Control and Prevention. Good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders. MMWR Recomm Rep 2012;61:1–44
   Google Scholar
• Meyburg J, Schulze A, Kohlmueller D, et al. Acylcarnitine profiles of preterm infants over the first four weeks of life. Pediatr Res 2002;52:720–3
   PubMed Web of Science ®Google Scholar
• Mandour I, El Gayar D, Amin M, et al. Amino acid and acylcarnitine profiles in premature neonates: a pilot study. Indian J Pediatr 2013;80:736--44
   PubMed Web of Science ®Google Scholar
• De T, Kruthika-Vinod TP, Nagaraja D, Christopher R. Postnatal variations in blood free and acylcarnitines. J Clin Lab Anal 2011;25:126–9
   Google Scholar
• Shigematsu Y, Hata I, Tajima G. Useful second-tier tests in expanded newborn screening of isovaleric acidemia and methylmalonic aciduria. J Inherit Metab Dis 2010;33:S283–8
   Google Scholar
• la Marca G, Malvagia S, Pasquini E, et al. Rapid 2nd-tier test for measurement of 3-OH-propionic and methylmalonic acids on dried blood spots: reducing the false-positive rate for propionylcarnitine during expanded newborn screening by liquid chromatography-tandem mass spectrometry. Clin Chem 2007;53:1364–9
   PubMed Web of Science ®Google Scholar
• Baker MW, Groose M, Hoffman G, et al. Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening. J Cyst Fibros 2011;10:278–81
   PubMed Web of Science ®Google Scholar
• Sarafoglou K, Banks K, Gaviglio A, et al. Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia. Pediatrics 2012;130:1261–8
   Google Scholar
• McHugh D, Cameron CA, Abdenur JE, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 2011;13:230–54
   PubMed Web of Science ®Google Scholar
• Marquardt G, Currier R, McHugh DM, et al. Enhanced interpretation of newborn screening results without analyte cutoff values. Genet Med 2012;14:648–55
   PubMed Web of Science ®Google Scholar
• Barden HS, Kessel R, Schuett VE. The costs and benefits of screening for PKU in Wisconsin. Soc Biol 1984;31:1–17
   PubMed Web of Science ®Google Scholar
• Lord J, Thomason MJ, Littlejohns P, et al. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. J Epidemiol Community Health 1999;53:179–86
   PubMed Web of Science ®Google Scholar
• Layde PM, Von Allmen SD, Oakley GP Jr. Congenital hypothyroidism control programs. A cost-benefit analysis. J Am Med Assoc 1979;241:2290–2
   PubMed Web of Science ®Google Scholar
• Dhondt JL, Farriaux JP, Sailly JC, Lebrun T. Economic evaluation of cost-benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism. J Inherit Metab Dis 1991;14:633–9
   Google Scholar
• Delange F. Neonatal screening for congenital hypothyroidism: results and perspectives. Horm Res 1997;48:51–61
   PubMedGoogle Scholar
• Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics 2003;112:1005–15
   PubMed Web of Science ®Google Scholar
• Prosser LA, Kong CY, Rusinak D, Waisbren SL. Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics 2010;125:e286–94
   PubMed Web of Science ®Google Scholar
• Thomason MJ, Lord J, Bain MD, et al. A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. J Public Health Med 1998;20:331–43
   Google Scholar
• Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr 2002;141:524–31
   PubMed Web of Science ®Google Scholar
• Filiano JJ, Bellimer SG, Kunz PL. Tandem mass spectrometry and newborn screening: pilot data and review. Pediatr Neurol 2002;26:201–4
   Google Scholar
• Klose DA, Kolker S, Heinrich B, et al. Incidence and short-term outcome of children with symptomatic presentation of organic acid and fatty acid oxidation disorders in Germany. Pediatrics 2002;110:1204–11
   Google Scholar
• Schoen EJ, Baker JC, Colby CJ, To TT. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 2002;110:781–6
   PubMed Web of Science ®Google Scholar
• Lindner M, Ho S, Fang-Hoffmann J, et al. Neonatal screening for glutaric aciduria type I: strategies to proceed. J Inherit Metab Dis 2006;29:378–82
   PubMedGoogle Scholar
• Dionisi-Vici C, Deodato F, et al. ‘Classical’ organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: long-term outcome and effects of expanded newborn screening using tandem mass spectrometry. J Inherit Metab Dis 2006;29:383–9
   PubMed Web of Science ®Google Scholar
• Cipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. Value Health 2007;10:83–97
   PubMed Web of Science ®Google Scholar
• Boneh A, Beauchamp M, Humphrey M, et al. Newborn screening for glutaric aciduria type I in Victoria: treatment and outcome. Mol Genet Metab 2008;94:287–91
   Google Scholar
• Wilcken B, Haas M, Joy P, et al. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 2009;124:e241–8
   PubMed Web of Science ®Google Scholar
• Grunert SC, Wendel U, Lindner M, et al. Clinical and neurocognitive outcome in symptomatic isovaleric acidemia. Orphanet J Rare Dis 2012;7(9):1--9
   Google Scholar
• Seymour CA, Thomason MJ, Chalmers RA, et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1997;1:1–95
   Google Scholar
• Hanley WB. False-positive results in expanded newborn screening. Pediatrics 2007;119:414–5
   Google Scholar
• El-Hattab AW, Li FY, Shen J, et al. Maternal systemic primary carnitine deficiency uncovered by newborn screening: clinical, biochemical, and molecular aspects. Genet Med 2010;12:19–24
   Google Scholar
• Lin HJ, Neidich JA, Salazar D, et al. Asymptomatic maternal combined homocystinuria and methylmalonic aciduria (cblC) detected through low carnitine levels on newborn screening. J Pediatr 2009;155:924–7
   Google Scholar
• Hinton CF, Ojodu JA, Fernhoff PM, et al. Maternal and neonatal vitamin B12 deficiency detected through expanded newborn screening - United States, 2003–2007. J Pediatr 2010;157:162–3
   PubMedGoogle Scholar
• Couce ML, Castineiras DE, Boveda MD, et al. Evaluation and long-term follow-up of infants with inborn errors of metabolism identified in an expanded screening programme. Mol Genet Metab 2011;104:470–5
   PubMed Web of Science ®Google Scholar
• Lindner M, Gramer G, Haege G, et al. Efficacy and outcome of expanded newborn screening for metabolic diseases–report of 10 years from South-West Germany. Orphanet J Rare Dis 2011;6(44):1--10
   Google Scholar
• Singh RH, Hinman AR. Newborn dried bloodspot screening: long-term follow-up activities and information system requirements. Genet Med 2010;12:S261–6
   Google Scholar
• Lam CW, Lai CK, Chow CB, et al. Ethnic-specific splicing mutation of the carnitine-acylcarnitine translocase gene in a Chinese neonate presenting with sudden unexpected death. Chin Med J (Engl) 2003;116:1110–2
   Google Scholar
• Lee RS, Lam CW, Lai CK, et al. Carnitine-acylcarnitine translocase deficiency in three neonates presenting with rapid deterioration and cardiac arrest. Hong Kong Med J 2007;13:66–8
   Google Scholar
• Frazier DM, Millington DS, McCandless SE, et al. The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005. J Inherit Metab Dis 2006;29:76–85
   PubMed Web of Science ®Google Scholar
• Wilson C, Kerruish NJ, Wilcken B, et al. Diagnosis of disorders of intermediary metabolism in New Zealand before and after expanded newborn screening: 2004–2009. N Z Med J 2012;125:42–50
   Google Scholar
• Chace DH, Pons R, Chiriboga CA, et al. Neonatal blood carnitine concentrations: normative data by electrospray tandem mass spectometry. Pediatr Res 2003;53:823–9
   PubMed Web of Science ®Google Scholar
• Sander J, Janzen N, Peter M, et al. Newborn screening for hepatorenal tyrosinemia: tandem mass spectrometric quantification of succinylacetone. Clin Chem 2006;52:482–7
   PubMed Web of Science ®Google Scholar
• la Marca G, Malvagia S, Pasquini E, et al. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs. Rapid Commun Mass Spectrom 2008;22:812–8
   Web of Science ®Google Scholar
• Stadler SC, Polanetz R, Maier EM, et al. Newborn screening for 3-methylcrotonyl-CoA carboxylase deficiency: population heterogeneity of MCCA and MCCB mutations and impact on risk assessment. Hum Mutat 2006;27:748–59
   Google Scholar
• Arnold GL, Koeberl DD, Matern D, et al. A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab 2008;93:363–70
   Google Scholar
• van Maldegem BT, Duran M, Wanders RJ, et al. Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency. JAMA 2006;296:943–52
   PubMed Web of Science ®Google Scholar
• Waisbren SE, Levy HL, Noble M, et al. Short-chain acyl-CoA dehydrogenase (SCAD) deficiency: an examination of the medical and neurodevelopmental characteristics of 14 cases identified through newborn screening or clinical symptoms. Mol Genet Metab 2008;95:39–45
   Google Scholar
• Jethva R, Ficicioglu C. Clinical outcomes of infants with short-chain acyl-coenzyme A dehydrogenase deficiency (SCADD) detected by newborn screening. Mol Genet Metab 2008;95:241–2
   Google Scholar
• Bleicher A. Perils of newborn screening: doctors may be testing infants for too many diseases. Sci Am 2012;307:30–1
   Google Scholar
• Ross LF. Newborn screening for lysosomal storage diseases: an ethical and policy analysis. J Inherit Metab Dis 2012;35:627–34
   PubMed Web of Science ®Google Scholar
• Ross LF, Waggoner DJ. Parents: critical stakeholders in expanding newborn screening. J Pediatr 2012;161:385–9
   Google Scholar
• Kai J, Ulph F, Cullinan T, Qureshi N. Communication of carrier status information following universal newborn screening for sickle cell disorders and cystic fibrosis: qualitative study of experience and practice. Health Technol Assess 2009;13:1–82, iii
   PubMed Web of Science ®Google Scholar
• Miller FA, Paynter M, Hayeems RZ, et al. Understanding sickle cell carrier status identified through newborn screening: a qualitative study. Eur J Hum Genet 2010;18:303–8
   PubMed Web of Science ®Google Scholar
• Farrell MH, Christopher SA. Frequency of high-quality communication behaviors used by primary care providers of heterozygous infants after newborn screening. Patient Educ Couns 2013;90:226–32
   Google Scholar
• Berry SA, Brown C, Grant M, et al. Newborn screening 50 years later: access issues faced by adults with PKU. Genet Med 2013;15:591--9
   PubMed Web of Science ®Google Scholar
• Wiley V, Carpenter K, Bayliss U, Wilcken B. Newborn screening–is it really that simple? Southeast Asian J Trop Med Public Health 2003;34:107–10
   Google Scholar
• Lin WD, Wu JY, Lai CC, et al. A pilot study of neonatal screening by electrospray ionization tandem mass spectrometry in Taiwan. Acta Paediatr Taiwan 2001;42:224–30
   Google Scholar
• Chace DH, Kalas TA, Naylor EW. The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genomics Hum Genet 2002;3:17–45
   PubMed Web of Science ®Google Scholar
• McCabe LL, McCabe ER. Expanded newborn screening: implications for genomic medicine. Annu Rev Med 2008;59:163–75
   Google Scholar
• Buyukgebiz A. Newborn screening for congenital hypothyroidism. J Pediatr Endocrinol Metab 2006;19:1291–8
   PubMed Web of Science ®Google Scholar
• Lafranchi SH. Newborn screening strategies for congenital hypothyroidism: an update. J Inherit Metab Dis 2010;33:S225–33
   PubMedGoogle Scholar
• Weng YH, Chou YH, Lien RI. Hyperbilirubinemia in healthy neonates with glucose-6-phosphate dehydrogenase deficiency. Early Hum Dev 2003;71:129–36
   PubMed Web of Science ®Google Scholar
• Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 2003;290:2564–72
   PubMed Web of Science ®Google Scholar
• Tu WJ, He J, Chen H, et al. Psychological effects of false-positive results in expanded newborn screening in China. PLoS One 2012;7:e36235
   Google Scholar
• Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics 2006;117:1915–21
   PubMed Web of Science ®Google Scholar
• Tarini BA, Christakis DA, Welch HG. State newborn screening in the tandem mass spectrometry era: more tests, more false-positive results. Pediatrics 2006;118:448–56
   PubMed Web of Science ®Google Scholar
• Tarini BA. The current revolution in newborn screening: new technology, old controversies. Arch Pediatr Adolesc Med 2007;161:767–72
   PubMed Web of Science ®Google Scholar
• Prosser LA, Ladapo JA, Rusinak D, Waisbren SE. Parental tolerance of false-positive newborn screening results. Arch Pediatr Adolesc Med 2008;162:870–6
   PubMedGoogle Scholar
• Hayeems RZ, Miller FA, Bombard Y, et al. Expectations and values about expanded newborn screening: a public engagement study. Health Expect 2013; doi: 10.1111/hex.12047
   Google Scholar
• Dixon S, Shackley P, Bonham J, Ibbotson R. Putting a value on the avoidance of false positive results when screening for inherited metabolic disease in the newborn. J Inherit Metab Dis 2012;35:169–76
   Google Scholar
• Hewlett J, Waisbren SE. A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J Inherit Metab Dis 2006;29:677–82
   PubMed Web of Science ®Google Scholar
• Deluca JM, Kearney MH, Norton SA, Arnold GL. Internet use by parents of infants with positive newborn screens. J Inherit Metab Dis 2012;35:879–84
   Google Scholar
• Fingerhut R. Recall rate and positive predictive value of MSUD screening is not influenced by hydroxyproline. Eur J Pediatr 2009;168:599–604
   Google Scholar
• Oglesbee D, Sanders KA, Lacey JM, et al. Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD). Clin Chem 2008;54:542–9
   PubMed Web of Science ®Google Scholar
• Chalcraft KR, Britz-McKibbin P. Newborn screening of inborn errors of metabolism by capillary electrophoresis-electrospray ionization-mass spectrometry: a second-tier method with improved specificity and sensitivity. Anal Chem 2009;81:307–14
   PubMed Web of Science ®Google Scholar
• Rothenberg MB, Sills EM. Iatrogenesis: the PKU anxiety syndrome. J Am Acad Child Psychiatry 1968;7:689–92
   PubMedGoogle Scholar
• Liebl B, Nennstiel-Ratzel U, von Kries R, et al. Very high compliance in an expanded MS-MS-based newborn screening program despite written parental consent. Prev Med 2002;34:127–31
   PubMed Web of Science ®Google Scholar
• Faden R, Chwalow AJ, Holtzman NA, Horn SD. A survey to evaluate parental consent as public policy for neonatal screening. Am J Public Health 1982;72:1347–52
   PubMed Web of Science ®Google Scholar
• Detmar S, Hosli E, Dijkstra N, et al. Information and informed consent for neonatal screening: opinions and preferences of parents. Birth 2007;34:238–44
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Committee Opinion No. 481: Newborn screening. Obstet Gynecol 2011;117:762–5
   Google Scholar
• Rose NC, Dolan SM. Newborn screening and the obstetrician. Obstet Gynecol 2012;120:908–17
   Google Scholar
• Wildeman S, Downie J. Genetic and metabolic screening of newborns: must health care providers seek explicit parental consent? Health Law J 2001;9:61–111
   PubMedGoogle Scholar
• Miller FA, Hayeems RZ, Carroll JC, et al. Consent for newborn screening: the attitudes of health care providers. Public Health Genomics 2010;13:181–90
   Google Scholar
• Huang MC, Lin SJ. Newborn screening: should explicit parental consent be required? Acta Paediatr Taiwan 2003;44:126–9
   Google Scholar
• Gennaccaro M, Waisbren SE, Marsden D. The knowledge gap in expanded newborn screening: survey results from paediatricians in Massachusetts. J Inherit Metab Dis 2005;28:819–24
   Web of Science ®Google Scholar
• Dunn L, Gordon K, Sein J, Ross K. Universal newborn screening: knowledge, attitudes, and satisfaction among public health professionals. South Med J 2012;105:218–22
   Google Scholar
• Morales A, Wierenga A, Cuthbert C, et al. Expanded newborn screening in Puerto Rico and the US Virgin Islands: education and barriers assessment. Genet Med 2009;11:169–75
   Google Scholar
• Wells AS, Northrup H, Crandell SS, et al. Expanded newborn screening in Texas: a survey and educational module addressing the knowledge of pediatric residents. Genet Med 2009;11:163–8
   Google Scholar
• Anderson CS, Bentler K, Vanderburg N, Berry SA. The quality of metabolic newborn screening specialty care services: results of a survey of primary care providers. Minn Med 2012;95:45–9
   Google Scholar
• Deluca J, Zanni KL, Bonhomme N, Kemper AR. Implications of newborn screening for nurses. J Nurs Scholarsh 2013;45:25–33
   Google Scholar
• Nicholls SG, Southern KW. Parental information use in the context of newborn bloodspot screening. An exploratory mixed methods study. J Community Genet 2012;3:251–7
   Google Scholar
• McCann PJ. Agency discretion and public health service delivery. Health Serv Res 2009;44:1897–908
   Google Scholar
• Couzin-Frankel J. Newborn blood collections. Science gold mine, ethical minefield. Science 2009;324:166–8
   Google Scholar
• Hoff R, Berardi VP, Weiblen BJ, et al. Seroprevalence of human immunodeficiency virus among childbearing women. Estimation by testing samples of blood from newborns. N Engl J Med 1988;318:525–30
   PubMed Web of Science ®Google Scholar
• Henderson LO, Powell MK, Hannon WH, et al. An evaluation of the use of dried blood spots from newborn screening for monitoring the prevalence of cocaine use among childbearing women. Biochem Mol Med 1997;61:143–51
   PubMedGoogle Scholar
• Chaudhuri SN, Butala SJ, Ball RW, Braniff CT. Pilot study for utilization of dried blood spots for screening of lead, mercury and cadmium in newborns. J Expo Sci Environ Epidemiol 2009;19:298–316
   PubMedGoogle Scholar
• Abdallah MW, Larsen N, Mortensen EL, et al. Neonatal levels of cytokines and risk of autism spectrum disorders: an exploratory register-based historic birth cohort study utilizing the Danish Newborn Screening Biobank. J Neuroimmunol 2012;252:75–82
   PubMed Web of Science ®Google Scholar
• Botkin JR, Rothwell E, Anderson R, et al. Public attitudes regarding the use of residual newborn screening specimens for research. Pediatrics 2012;129:231–8
   PubMed Web of Science ®Google Scholar
• Gong LM, Tu WJ, He J, et al. The use of newborn screening dried blood spots for research: the parental perspective. J Bioeth Inq 2012;9:189–93
   Google Scholar
• Norgaard-Pedersen B, Hougaard DM. Storage policies and use of the Danish Newborn Screening Biobank. J Inherit Metab Dis 2007;30:530–6
   PubMed Web of Science ®Google Scholar
• Hu S. Minnesota Supreme Court hears whether the Genetic Privacy Act protects newborn blood spot samples obtained under the state's newborn screening statutes–Bearder v. State of Minnesota. Am J Law Med 2012;38:225–7
   Google Scholar
• Haga SB. Analysis of educational materials and destruction/opt-out initiatives for storage and use of residual newborn screening samples. Genet Test Mol Biomarkers 2010;14:587–92
   Google Scholar
• Rothwell EW, Anderson RA, Burbank MJ, et al. Concerns of newborn blood screening advisory committee members regarding storage and use of residual newborn screening blood spots. Am J Public Health 2011;101:2111–6
   Google Scholar
• Bowman DM, Studdert DM. Newborn screening cards: a legal quagmire. Med J Aust 2011;194:319–22
   PubMed Web of Science ®Google Scholar
• Botkin JR, Goldenberg AJ, Rothwell E, et al. Retention and research use of residual newborn screening bloodspots. Pediatrics 2013;131:120–7
   Google Scholar
• Therrell BL, Wu C. Including the initial newborn screening bloodspot collection device serial number on birth certificates: basis and recommendations from the Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children. Genet Med 2013;15:229–33
   Google Scholar
• Gelb MH, Turecek F, Scott CR, Chamoles NA. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis 2006;29:397–404
   PubMed Web of Science ®Google Scholar
• Kasper DC, Herman J, De Jesus VR, et al. The application of multiplexed, multi-dimensional ultra-high-performance liquid chromatography/tandem mass spectrometry to the high-throughput screening of lysosomal storage disorders in newborn dried bloodspots. Rapid Commun Mass Spectrom 2010;24:986–94
   PubMed Web of Science ®Google Scholar
• Marsden D, Levy H. Newborn Screening of Lysosomal Storage Disorders. Clin Chem 2010;56:1071–9
   PubMed Web of Science ®Google Scholar
• Legnini E, Orsini JJ, Muhl A, et al. Analysis of acid sphingomyelinase activity in dried blood spots using tandem mass spectrometry. Ann Lab Med 2012;32:319–23
   Google Scholar
• Hubbard WC, Moser AB, Tortorelli S, et al. Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings. Mol Genet Metab 2006;89:185–7
   PubMedGoogle Scholar
• Funke S, Gardeitchik T, Kouwenberg D, et al. Perinatal and early infantile symptoms in congenital disorders of glycosylation. Am J Med Genet A 2013;161:578–84
   Google Scholar
• Mercimek-Mahmutoglu S, Sinclair G, van Dooren SJ, et al. Guanidinoacetate methyltransferase deficiency: first steps to newborn screening for a treatable neurometabolic disease. Mol Genet Metab 2012;107:433–7
   Google Scholar
• Pang S, Shook MK. Current status of neonatal screening for congenital adrenal hyperplasia. Curr Opin Pediatr 1997;9:419–23
   Google Scholar
• Rhoades E, King P. Public health explores expanding newborn screening for cystic fibrosis, congenital adrenal hyperplasia, and medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD). J Okla State Med Assoc 2001;94:129–32
   Google Scholar
• Gleeson HK, Wiley V, Wilcken B, et al. Two-year pilot study of newborn screening for congenital adrenal hyperplasia in New South Wales compared with nationwide case surveillance in Australia. J Paediatr Child Health 2008;44:554–9
   Google Scholar
• Warne GL, Armstrong KL, Faunce TA, et al. The case for newborn screening for congenital adrenal hyperplasia in Australia. Med J Aust 2010;192:107
   Google Scholar
• Gucciardi A, Pirillo P, Di Gangi IM, et al. A rapid UPLC-MS/MS method for simultaneous separation of 48 acylcarnitines in dried blood spots and plasma useful as a second-tier test for expanded newborn screening. Anal Bioanal Chem 2012;404:741–51
   Google Scholar
• Miller JHt, Poston PA, Karnes HT. A quantitative method for acylcarnitines and amino acids using high resolution chromatography and tandem mass spectrometry in newborn screening dried blood spot analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2012;903:142–9
   PubMed Web of Science ®Google Scholar
• Britz-McKibbin P. Expanded newborn screening of inborn errors of metabolism by capillary electrophoresis-electrospray ionization-mass spectrometry (CE-ESI-MS). Methods Mol Biol 2013;919:43–56
   Google Scholar
• Yang Q, Manicke NE, Wang H, et al. Direct and quantitative analysis of underivatized acylcarnitines in serum and whole blood using paper spray mass spectrometry. Anal Bioanal Chem 2012;404:1389–97
   PubMed Web of Science ®Google Scholar
• Wang C, Zhu H, Cai Z, et al. Newborn screening of phenylketonuria using direct analysis in real time (DART) mass spectrometry. Anal Bioanal Chem 2013;405:3159–64
   PubMed Web of Science ®Google Scholar
• Thompson JW, Zhang H, Smith P, et al. Extraction and analysis of carnitine and acylcarnitines by electrospray ionization tandem mass spectrometry directly from dried blood and plasma spots using a novel autosampler. Rapid Commun Mass Spectrom 2012;26:2548–54
   Google Scholar
• Shih SC, Yang H, Jebrail MJ, et al. Dried blood spot analysis by digital microfluidics coupled to nanoelectrospray ionization mass spectrometry. Anal Chem 2012;84:3731–8
   PubMed Web of Science ®Google Scholar
• Denes J, Szabo E, Robinette SL, et al. Metabonomics of newborn screening dried blood spot samples: a novel approach in the screening and diagnostics of inborn errors of metabolism. Anal Chem 2012;84:10113–20
   PubMed Web of Science ®Google Scholar
• Baker MW, Grossman WJ, Laessig RH, et al. Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol 2009;124:522–7
   PubMed Web of Science ®Google Scholar
• Baker MW, Laessig RH, Katcher ML, et al. Implementing routine testing for severe combined immunodeficiency within Wisconsin's newborn screening program. Public Health Rep 2010;125:88–95
   Google Scholar
• Comeau AM, Hale JE, Pai SY, et al. Guidelines for implementation of population-based newborn screening for severe combined immunodeficiency. J Inherit Metab Dis 2010;33(Suppl 2):S273--81
   PubMed Web of Science ®Google Scholar
• Lipstein EA, Vorono S, Browning MF, et al. Systematic evidence review of newborn screening and treatment of severe combined immunodeficiency. Pediatrics 2010;125:e1226–35
   PubMed Web of Science ®Google Scholar
• Schwarz E, Liu A, Randall H, et al. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. Pediatr Res 2009;66:230–5
   Web of Science ®Google Scholar
• Chace DH, Hannon WH. Impact of second-tier testing on the effectiveness of newborn screening. Clin Chem 2010;56:1653–5
   PubMed Web of Science ®Google Scholar
• Tortorelli S, Turgeon CT, Lim JS, et al. Two-tier approach to the newborn screening of methylenetetrahydrofolate reductase deficiency and other remethylation disorders with tandem mass spectrometry. J Pediatr 2010;157:271–5
   PubMed Web of Science ®Google Scholar
• Goldenberg AJ, Sharp RR. The ethical hazards and programmatic challenges of genomic newborn screening. JAMA 2012;307:461–2
   Google Scholar
• Solomon BD, Pineda-Alvarez DE, Bear KA, et al. Applying Genomic Analysis to Newborn Screening. Mol Syndromol 2012;3:59–67
   Google Scholar
• Alexander D, van Dyck PC. A vision of the future of newborn screening. Pediatrics 2006;117:S350–4
   PubMed Web of Science ®Google Scholar
• Greeley SA, Msall ME, Acharya K. Genomic sequencing in newborn screening programs. JAMA 2012;307:2146–7
   Google Scholar
• Schimmenti LA, Warman B, Schleiss MR, et al. Evaluation of newborn screening bloodspot-based genetic testing as second tier screen for bedside newborn hearing screening. Genet Med 2011;13:1006–10
   Google Scholar
• Tarini BA, Goldenberg AJ. Ethical issues with newborn screening in the genomics era. Annu Rev Genomics Hum Genet 2012;13:381–93
   PubMed Web of Science ®Google Scholar
• Dondorp WJ, de Wert GM, Niermeijer MF. Genomic sequencing in newborn screening programs. JAMA 2012;307:2146
   Google Scholar
• Mak CM, Lam KS, Tan KC, Ma OC, Tam S. Cerebrotendinous xanthomatosis in a Hong Kong Chinese kinship with a novel splicing site mutation IVS6-1G > T in the sterol 27-hydroxylase gene. Mol Genet Metab 2004;81:144–6
   Google Scholar
• Ng YW, Chan AO, Au Yeung YT, et al. Hyperammonaemic encephalopathy in an adult patient with citrin deficiency associated with a novel mutation. Hong Kong Med J 2011;17:410–3
   Google Scholar
• Cernik C, Haller N, Mostow EN. Adult-onset erythropoietic porphyria in the setting of MDS. Arch Dermatol 2009;145:948–9
   Google Scholar
• Telman G, Kouperberg E, Sprecher E, Yarnitsky D. Distribution of etiologies in patients above and below age 45 with first-ever ischemic stroke. Acta Neurol Scand 2008;117:311–6
   Google Scholar
• Rolfs A, Bottcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005;366:1794–6
   PubMed Web of Science ®Google Scholar
• Brouns R, Sheorajpanday R, Braxel E, et al. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg 2007;109:479–84
   PubMed Web of Science ®Google Scholar
• Mak CM, Lam CW, Fan ST, et al. Genetics of familial amyloidotic polyneuropathy in a Hong Kong Chinese kindred. Acta Neurol Scand 2003;107:419–22
   PubMed Web of Science ®Google Scholar
• Mak CM, Kwong YL, Lam CW, et al. Identification of a novel TTR Gly67Glu mutant and the first case series of familial transthyretin amyloidosis in Hong Kong Chinese. Amyloid 2007;14:293–7
   PubMed Web of Science ®Google Scholar
• Chang CM, Yu YL, Wong M, et al. Type I familial amyloid polyneuropathy in a Chinese family. Acta Neurol Scand 1989;79:391–6
   PubMed Web of Science ®Google Scholar
• Neil JF, Glew RH, Peters SP. Familial psychosis and diverse neurologic abnormalities in adult-onset Gaucher's disease. Arch Neurol 1979;36:95–9
   Google Scholar
• Sakushima K, Tsuji-Akimoto S, Niino M, et al. Adult Leigh disease without failure to thrive. Neurologist 2011;17:222–7
   Google Scholar
• Feillet F, Steinmann G, Vianey-Saban C, et al. Adult presentation of MCAD deficiency revealed by coma and severe arrythmias. Intensive Care Med 2003;29:1594–7
   PubMed Web of Science ®Google Scholar
• Wilhelm GW. Sudden death in a young woman from medium chain acyl-coenzyme A dehydrogenase (MCAD) deficiency. J Emerg Med 2006;30:291–4
   Google Scholar
• Jurecka A, Golda A, Opoka-Winiarska V, et al. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) with a predominantly cardiac phenotype. Mol Genet Metab 2011;104:695–9
   Google Scholar
• Mak CM, Sheng B, Lee HH, et al. Young-onset parkinsonism in a Hong Kong Chinese man with adult-onset Hallervorden-Spatz syndrome. Int J Neurosci 2011;121:224–7
   PubMed Web of Science ®Google Scholar
• Iaselli F, Rea G, Cappabianca S, et al. Adult-onset pulmonary involvement in Niemann-Pick disease type B. Monaldi Arch Chest Dis 2011;75:235–40
   Google Scholar
• Rohininath T, Costello DJ, Lynch T, et al. Fatal presentation of ornithine transcarbamylase deficiency in a 62-year-old man and family studies. J Inherit Metab Dis 2004;27:285–8
   PubMed Web of Science ®Google Scholar
• Klein OD, Kostiner DR, Weisiger K, et al. Acute fatal presentation of ornithine transcarbamylase deficiency in a previously healthy male. Hepatol Int 2008;2:390–4
   Google Scholar
• Bezinover D, Douthitt L, McQuillan PM, et al. Fatal hyperammonemia after renal transplant due to late-onset urea cycle deficiency: a case report. Transplant Proc 2010;42:1982–5
   PubMedGoogle Scholar
• Ben-Ari Z, Dalal A, Morry A, et al. Adult-onset ornithine transcarbamylase (OTC) deficiency unmasked by the Atkins' diet. J Hepatol 2010;52:292–5
   Google Scholar
• Thakur V, Rupar CA, Ramsay DA, et al. Fatal cerebral edema from late-onset ornithine transcarbamylase deficiency in a juvenile male patient receiving valproic acid. Pediatr Crit Care Med 2006;7:273–6
   PubMed Web of Science ®Google Scholar
• Kazama-Saegusa S, Kazama JJ, Sugaya H, et al. A case of late onset primary hyperoxaluria type I (PH-I) presented with black liver. Clin Nephrol 1998;50:184–7
   Google Scholar
• Karadag S, Gursu M, Aydin Z, et al. Primary hyperoxaluria in an adult presenting with end-stage renal failure together with hypercalcemia and hypothyroidism. Hemodial Int 2011;15:573–6
   Google Scholar
• Hurowitz GI, Silver JM, Brin MF, et al. Neuropsychiatric aspects of adult-onset Tay-Sachs disease: two case reports with several new findings. J Neuropsychiatry Clin Neurosci 1993;5:30–6
   Google Scholar
• Seto WK, Mak CM, But D, et al. Mutational analysis for Wilson's disease. Lancet 2009;374:662
   Google Scholar
• Garside S, Rosebush PI, Levinson AJ, Mazurek MF. Late-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms. J Clin Psychiatry 1999;60:460–8
   PubMedGoogle Scholar
• Mak CM, Lam KS, Ma OC, et al. Novel insertion 496_497insG creating a stop codon D194X in a Chinese family with X-Linked adrenoleukodystrophy. Horm Res 2005;63:1–5
   Google Scholar
• Furuhashi Y, Ishikawa M. Adult-onset adrenoleukodystrophy heralded by auditory hallucinations and delusions. Psychosomatics 2011;52:492–3
   Google Scholar